Savant HWP Inc.
Aiming to interrupt addictions, at a basic level
This article was originally published in Start Up
The founders of Savant HWP Inc. believe they have identified a molecule that could prove effective in treating many kinds of substance as well as behavioral addictions, because it appears to influence relevant brain chemistry at a fundamental level. Its compound binds to the alpha-3-beta-4 nicotinic acetylcholine receptor and appears to indirectly regulate production of dopamine in the mid-brain.
You may also be interested in...
Antibiotic incentives, vaccine strategies, drug pricing, patent updates and more hot topics from the Biotechnology Innovation Organization's recent annual conference.
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.